Researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific ...

Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails ...

New York, NY (September 1, 2022) — Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line ...

Immunocore Limited presented data from the IMCgp100-102 trial at the American Society of Clinical Oncology meeting that showed a durable response and strong overall survival rate in patients with ...

Washington [US], September 2 (ANI): Researchers have published results that show encouraging therapeutic options for patients with blood cancer and multiple myeloma after first-line treatment with ...

T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and/or bispecific antibody (BsAb) has been established and become a promising treatment strategy for relapsed/refractory B-cell ...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Talvey (talquetamab-tgvs), a first-in-class ...

A version of this article was originally published on CancerNetwork. This version has been lightly edited. The FDA has granted accelerated approval to talquetamab-tgvs (Talvey) for patients with ...